Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Arrowhead Pharmaceuticals reports strong Q1 earnings and outlines growth strategy

Arrowhead Pharmaceuticals showcased solid financial performance, promising clinical outcomes, and a strategic growth plan during the Q1 2023 earnings call.
While facing challenges in financial losses and program complexities, the company's strengths in innovation, partnerships, and pipeline development position them for future success.
Opportunities lie in upcoming data releases, therapeutic advancements, and strategic collaborations, offering avenues for market expansion and medical breakthroughs.
Overall, Arrowhead Pharmaceuticals demonstrates resilience, innovation, and a clear vision for growth in the competitive biopharmaceutical landscape.

Arrowhead Pharmaceuticals reports robust Q2 earnings and expands pipeline

Arrowhead Pharmaceuticals delivered strong financial results and showcased progress in its drug pipeline, particularly in the pulmonary and CNS spaces.
While facing challenges in translating preclinical success to clinical outcomes and navigating competitive landscapes, the company's strategic partnerships and efficient cost management are key strengths.
Opportunities lie in expanding into new therapeutic areas, leveraging external interest for internal development, and benefiting from regulatory insights in the CNS field.
Overall, Arrowhead Pharmaceuticals remains well-positioned for future growth and innovation in the biopharmaceutical sector.

Arrowhead Pharmaceuticals advances pipeline with strong financial backing

Arrowhead Pharmaceuticals made progress in de-risking its pulmonary franchise and advancing key cardiometabolic candidates.
The company's strong financial position and focus on partnerships support its goal of expanding the pipeline to 20 products by 2025.
Challenges include high operating expenses, the need for specific financing for trials, and managing cash burn effectively.
Exploration of CNS targets and upcoming Phase 2 data presentations offer growth opportunities for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals advances key products towards commercialization amid financial challenges

Arrowhead Pharmaceuticals made significant progress on key products and is advancing towards commercialization and de-risking their pipeline.
Despite facing a net loss, the company remains focused on expanding their product portfolio and exploring new treatment options.
Strategic partnerships and ongoing research efforts position Arrowhead well for future growth and potential commercial success.
Managing financial challenges and optimizing trial strategies will be crucial for Arrowhead's continued success in the biopharmaceutical industry.

Arrowhead Pharmaceuticals advances RNAi pipeline with cardiometabolic focus

Arrowhead Pharmaceuticals focuses on advancing RNAi therapeutics with a cardiometabolic emphasis.
Financials show a net loss with plans to strengthen the balance sheet and decrease operating expenses.
Exploring debt financing, partnerships, and new innovations for pipeline expansion and commercial growth.
Challenges include data delays, uncertain timelines, and the need for additional biomarker data.

Arrowhead Pharmaceuticals reports strong fiscal 2024 results and strategic partnerships

Arrowhead Pharmaceuticals' fiscal 2024 performance was robust, fueled by a game-changing partnership with Sarepta and promising results in the cardiometabolic pipeline.
While facing challenges in differentiation and portfolio management, the company's proactive approach and strong financial position present opportunities for growth and innovation.
Strategic collaborations, ongoing Phase III studies, and plans for debt repayment through partnership cash flows underscore Arrowhead's commitment to value creation and sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead reports fiscal 2021 first quarter earnings and holds a conference call

Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results

NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR).

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Arrowhead Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claims

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead files IND for ARO-ANG3 to start Phase 2b study in patients with mixed dyslipidemia

Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to release earnings and hold conference call on February 4 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results

ARWR is a leading RNAi therapeutics company with a vast pipeline and a decade-long history of research. Often, companies with a long history of research find themselves unable to protect their Intellectual Property from generics.

How Arrowhead Protects Its Intellectual Property

DuPont de Nemours

Intel

Thermo Fisher Scientific

Onto Innovation

Veeco Instruments

Seven nanotech stocks to buy have the potential to reward investors as innovation in the sector accelerates. The post 7 Nanotech Stocks To Buy With Huge Returns in Store appeared first on InvestorPlace.

7 Nanotech Stocks To Buy With Huge Returns in Store

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead completes collaboration and license agreement with Takeda Pharmaceutical Company Limited

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda

Advaxis

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs.

Why These 3 Pharma Stocks Are Moving Today

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q4 2020 Results - Earnings Call Transcript

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) decreased 2.49% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 536.36% over the past year to ($0.48), which missed the estimate of $0.12.

Recap: Arrowhead Pharmaceuticals Q4 Earnings

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced financial results for its fiscal year ended September 30, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive clinical data from multiple product candidates in its cardiometabolic pipeline at the American Heart Association

Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive interim clinical data at The AASLD Liver Meeting Digital Experience

Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will host KOL webinars on two investigational RNAi based cardiometabolic candidates ARO-APOC3 and ARO-ANG3

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will webcast its fiscal 2020 year end earnings

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results

CRISPR Therapeutics

These biotechs are fueling up for massive market launches.

2 Monster Young Biotech Stocks to Add to Your Watchlist

Despite a 3x growth since the March 18 lows of this year, at the current price of around $60 per share we believe Arrowhead (NASDAQ: ARWR), a biopharmaceutical company that develops RNA interference therapies, looks attractive and it can see significant upside from the current levels.

Arrowhead Stock Is Up 16x Since 2017, And The Rally Is Far From Over

Alkermes

Neurocrine Biosciences

ACADIA Pharma

BioMarin Pharmaceutical

Ionis Pharma

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma companies that have shown strong historical revenue growth, improving fundamentals, and yet have not rallied.

ACADIA, Neurocrine, Alkermes Are Out Of Favor. Is It Time To Buy?

Why Arrowhead Pharmaceuticals Stock Jumped Today

Arrowhead Pharmaceuticals establishes deal with Takeda for the use of ARO-AAT in a deal worth up to $1.04 billion.

Arrowhead Is A Buy On Takeda Deal And Massive Pipeline

Takeda Pharmaceutical

Arrowhead's New Deal With Takeda Strengthens The Company's Value Proposition

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to participate in Chardan Genetic Medicines Conference

Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference

Arrowhead Pharmaceuticals (ARWR) news for Wednesday includes positive interim results from a clinical trial pushing ARWR stock higher.
The post Arrowhead Pharmaceuticals News: Why ARWR Stock Is Shooting 45% Higher Today appeared first on InvestorPlace.

Arrowhead Pharmaceuticals News: Why ARWR Stock Is Shooting 45% Higher Today

Arrowhead Pharma posted positive clinical trials data on a promising drug to treat a rare genetic liver disease, and ARWR stock soared near a nine-moth high; shares of rival Dicerna also jumped.
The post Arrowhead Pharma Reveals Positive Data On Drug To Treat Liver Disease; ARWR Stock Jumps appeared first on Investor's Business Daily.

News for Arrowhead Pharmaceuticals Stock (ARWR)